- Home
- SGC vs BDSX Comparison
SGC vs BDSX Comparison
Compare SGC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- BDSX
- Stock Information
- Founded
- SGC 1920
- BDSX 2005
- Country
- SGC United States
- BDSX United States
- Employees
- SGC N/A
- BDSX N/A
- Industry
- SGC Apparel
- BDSX Precision Instruments
- Sector
- SGC Consumer Discretionary
- BDSX Health Care
- Exchange
- SGC Nasdaq
- BDSX Nasdaq
- Market Cap
- SGC 252.6M
- BDSX 257.0M
- IPO Year
- SGC N/A
- BDSX 2020
- Fundamental
- Price
- SGC $15.08
- BDSX $1.69
- Analyst Decision
- SGC Strong Buy
- BDSX Strong Buy
- Analyst Count
- SGC 2
- BDSX 4
- Target Price
- SGC $22.00
- BDSX $3.08
- AVG Volume (30 Days)
- SGC 87.1K
- BDSX 238.2K
- Earning Date
- SGC 11-04-2024
- BDSX 11-05-2024
- Dividend Yield
- SGC 3.69%
- BDSX N/A
- EPS Growth
- SGC N/A
- BDSX N/A
- EPS
- SGC 0.68
- BDSX N/A
- Revenue
- SGC $553,945,000.00
- BDSX $60,902,000.00
- Revenue This Year
- SGC $4.89
- BDSX $48.06
- Revenue Next Year
- SGC $4.84
- BDSX $29.97
- P/E Ratio
- SGC $22.08
- BDSX N/A
- Revenue Growth
- SGC 1.22
- BDSX 46.25
- 52 Week Low
- SGC $7.40
- BDSX $1.15
- 52 Week High
- SGC $21.80
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- SGC 50.89
- BDSX 44.40
- Support Level
- SGC $14.93
- BDSX $1.66
- Resistance Level
- SGC $15.62
- BDSX $1.80
- Average True Range (ATR)
- SGC 0.37
- BDSX 0.08
- MACD
- SGC 0.04
- BDSX -0.01
- Stochastic Oscillator
- SGC 40.59
- BDSX 38.46
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.